提交患者经验数据时的现行做法和挑战 美国食品和药物管理局的监管决策:行业调查
Cathy Anne Pinto1, Tommi Tervonen2, Cecilia Jimenez-Moreno3
1Merck & Co., Inc., Rahway, NJ, USA. cathy.pinto@merck.com.
The patient
|December 12, 2023
概括
行业寻求更清晰的途径提交患者体验数据 (PED) 美国食品和药物管理局 (FDA). 关键需求包括透明的决策和扩大FDA关于在监管审查中使用PED的指导.
科学领域:
- 监管科学 监管科学
- 患者报告的结果
- 卫生政策 卫生政策
背景情况:
- 美国食品和药物管理局 (FDA) 旨在增加在监管决策中使用患者体验数据 (PED).
- 行业利益相关者在提交和将PED整合到FDA备案中面临着挑战.
- 了解当前的做法和感知到的障碍对于优化PED利用至关重要.
研究的目的:
- 调查行业实践,并确定与提交患者体验数据 (PED) 相关的挑战,用于美国食品和药物管理局 (FDA) 的监管决策.
- 收集关于PED最佳使用和提交的见解,包括患者报告的结果 (PRO),自然史研究 (NHS) 和患者偏好 (PP).
主要方法:
- 一个由两部分组成的在线调查对行业和合同研究组织 (CRO) 成员进行,这些成员在PED和FDA提交方面有经验.
- 第1部分评估了PED的收集,提交和FDA的使用;第2部分涉及最好最坏的练习,以优先考虑PED倡议.
- 受访者至少有两年PRO,NHS或PP数据的经验,并有直接的FDA备案经验.
主要成果:
- 大多数受访者 (84%) 来自行业,具有PRO (86%) 和PP (50%) 数据的重要经验.
- 所有参与者都同意FDA会议应包括PED讨论,最好是在关键试验之前.
- 关键的挑战包括在没有明确的FDA使用计划的情况下证明PED的含有是合理的;关于共同开发FDA审查表和报告PED不使用原因的协议很高.
结论:
- 尽管有FDA的政策目标,但在PED提交途径和监管决策透明度方面仍然存在重大挑战.
- 需要对利用现有的FDA会议结构进行PED讨论进行调整.
- 建议共同开发审查表和加强FDA指导,以促进更大的PED整合.
更多相关视频
相关概念视频
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Pharmacovigilance
843
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
843
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Drug Control Governance: Regulatory Bodies and Their Impact
161
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
161
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Standards of Care II
656
Nurses bear specific legal responsibilities under several federal statutes, including:
656


